Last reviewed · How we verify
Tetanus Toxoid Adsorbed Vaccine
Tetanus Toxoid Adsorbed Vaccine is a Toxoid vaccine Biologic drug developed by Genentech, Inc.. It is currently FDA-approved for Active immunization against tetanus, Tetanus prophylaxis and booster immunization.
Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection.
Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection. Used for Active immunization against tetanus, Tetanus prophylaxis and booster immunization.
At a glance
| Generic name | Tetanus Toxoid Adsorbed Vaccine |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin (tetanospasmin) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated tetanus toxin (toxoid) adsorbed onto an aluminum salt adjuvant, which enhances the immune response. When administered, it triggers B and T cell responses that generate protective antibodies (antitoxins) against tetanus toxin produced by Clostridium tetani. This provides long-term immunity against tetanus disease.
Approved indications
- Active immunization against tetanus
- Tetanus prophylaxis and booster immunization
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) (PHASE1)
- Immunosuppression and COVID-19 Boosters (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
- Confirmatory Study of BK1310 in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetanus Toxoid Adsorbed Vaccine CI brief — competitive landscape report
- Tetanus Toxoid Adsorbed Vaccine updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI
Frequently asked questions about Tetanus Toxoid Adsorbed Vaccine
What is Tetanus Toxoid Adsorbed Vaccine?
How does Tetanus Toxoid Adsorbed Vaccine work?
What is Tetanus Toxoid Adsorbed Vaccine used for?
Who makes Tetanus Toxoid Adsorbed Vaccine?
What drug class is Tetanus Toxoid Adsorbed Vaccine in?
What development phase is Tetanus Toxoid Adsorbed Vaccine in?
What are the side effects of Tetanus Toxoid Adsorbed Vaccine?
What does Tetanus Toxoid Adsorbed Vaccine target?
Related
- Drug class: All Toxoid vaccine drugs
- Target: All drugs targeting Tetanus toxin (tetanospasmin)
- Manufacturer: Genentech, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Active immunization against tetanus
- Indication: Drugs for Tetanus prophylaxis and booster immunization
- Compare: Tetanus Toxoid Adsorbed Vaccine vs similar drugs
- Pricing: Tetanus Toxoid Adsorbed Vaccine cost, discount & access